Literature DB >> 12490971

Anti-thrombotic effects of atorvastatin--an effect unrelated to lipid lowering.

V Gaddam1, D Y Li, J L Mehta.   

Abstract

Statins (3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) have been shown to reduce clinical events in excess of what can be explained by altering lipid profile. Statins have been shown to possess modest antioxidant and antiplatelet aggregatory effect. We postulated that statins may accordingly inhibit arterial thrombus formation. To assess the antithrombotic effects of atorvastatin, a commonly used statin, in response to an oxidant stimulus, we fed Sprague-Dawley rats either regular chow, or chow mixed with atorvastatin (1.25 mg/kg) for 10 days (n = 16 in each group). Eight rats in each group were also given oxidized low-density lipoprotein intravenously prior to the induction of thrombus. An occlusive thrombus was created in the abdominal aorta by application of Whatman paper soaked in 35% FeCl3. The time to occlusive thrombus formation was not altered by administration of oxidized low-density lipoprotein in the rats fed regular chow or chow mixed with atorvastatin. However, time to thrombosis was increased in the group given chow mixed with atorvastatin (26 +/- 4 minutes vs. 20 +/- 5 minutes, P < 0.02). To determine the mechanism of atorvastatin's antithrombotic effect, we measured the expression of endothelial constitutive nitric oxide synthase (cNOS) in rat aortas by Western analysis. The cNOS protein expression was enhanced 75% in rats fed chow with atorvastatin (P < 0.01 vs. rats fed regular chow). Plasma levels of total cholesterol and low-density lipoprotein-cholesterol were similar in all groups. This study shows that atorvastatin delays thrombus formation in arterial channels exposed to oxidant stress. This effect of atorvastatin appears to be related to increased expression of cNOS, which is known to inhibit platelet aggregation and induce vasodilatation. The effects of atorvastatin are independent of its effects on plasma cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12490971     DOI: 10.1177/107424840200700408

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  12 in total

1.  Thrombophilia in ischemic stroke subtypes: implications for treatment.

Authors:  Cathy M Helgason
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-05

2.  Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin.

Authors:  T-C Chou; Y-F Lin; W-C Wu; K-M Chu
Journal:  Br J Pharmacol       Date:  2008-02-11       Impact factor: 8.739

3.  Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case-control study and a meta-analysis.

Authors:  Sergi Martinez-Ramirez; Raquel Delgado-Mederos; Rebeca Marín; Marc Suárez-Calvet; María Pilar Sáinz; Aída Alejaldre; Ángela Vidal-Jordana; Josep Lluís Martí-Vilalta; Joan Martí-Fàbregas
Journal:  J Neurol       Date:  2011-06-18       Impact factor: 4.849

Review 4.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

Review 5.  The anti-ischemic and anti-anginal properties of statins.

Authors:  Joel A Lardizabal; Prakash C Deedwania
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

6.  The many roles of statins in ischemic stroke.

Authors:  Jingru Zhao; Xiangjian Zhang; Lipeng Dong; Ya Wen; Lili Cui
Journal:  Curr Neuropharmacol       Date:  2014-12       Impact factor: 7.363

7.  Combination therapy reduces the incidence of no-reflow after primary per-cutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction.

Authors:  Shan-Shan Zhou; Feng Tian; Yun-Dai Chen; Jing Wang; Zhi-Jun Sun; Jun Guo; Qin-Hua Jin
Journal:  J Geriatr Cardiol       Date:  2015-03       Impact factor: 3.327

8.  Atorvastatin at reperfusion reduces myocardial infarct size in mice by activating eNOS in bone marrow-derived cells.

Authors:  Yikui Tian; Joel Linden; Brent A French; Zequan Yang
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

9.  Effect of statins on platelet function in patients with hyperlipidemia.

Authors:  Joanna Sikora; Barbara Kostka; Iwona Marczyk; Urszula Krajewska; Maciej Chałubiński; Marlena Broncel
Journal:  Arch Med Sci       Date:  2013-08-08       Impact factor: 3.318

10.  Effects of single-dose atorvastatin on interleukin-6, interferon gamma, and myocardial no-reflow in a rabbit model of acute myocardial infarction and reperfusion.

Authors:  X J Zhao; X L Liu; G X He; H P Xu
Journal:  Braz J Med Biol Res       Date:  2014-02-14       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.